CrushSCI.com
51.4Average days
34Median days
3Fastest days
236Longest days
3842025 publications

Paper Review Records

All Paper Review Records

30 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

4 days

Ravulizumab Shows Favorable Survival and Improves Clinical Markers in Children With HSCT ‐ TMA : Results of a Phase 3 Trial

Authors
Franco Locatelli; Michelle L. Schoettler; David Bueno‐Sánchez; Sonali Chaudhury; Jude Fry; Eric Bachman; Min Qin; Cynthia Carrillo‐Infante; Cory Williams; Aviva Krauss; Sarah Lawson; Yoshiyuki Takahashi; Hideki Sano; Daiichirou Hasegawa; Hyoung Jin Kang; Christopher C. DvorakShow moreShow less
Affiliations
1. Department of Pediatric Hematology and Oncology Istituto di Ricovero e Cura a Carattere Scientifico Bambino Gesù Children's Hospital and Catholic University of the Sacred Heart Rome Italy; 2. Aflac Cancer and Blood Disorders Center Children's Healthcare of Atlanta and Emory University School of Medicine Atlanta Georgia USA; 3. Pediatric Hematology and Oncology Department La Paz University Hospital Madrid Spain; 4. Stem Cell Transplantation and Cellular Therapies Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine Chicago Illinois USA; 5. Alexion, AstraZeneca Rare Disease Baar Switzerland; 6. Alexion, AstraZeneca Rare Disease Boston Massachusetts USA; 7. Department of Hematology—Oncology Schneider Children's Medical Center of Israel Petah Tikva Israel; 8. Department of Oncology and Hematology Birmingham Children's Hospital National Health Service Foundation Trust Birmingham UK; 9. Department of Pediatrics Nagoya University Graduate School of Medicine Nagoya Japan; 10. Department of Pediatric Oncology Fukushima Medical University Hospital Fukushima Japan; 11. Hyogo Prefectural Kobe Children's Hospital Kobe Japan; 12. Department of Pediatrics, Seoul National University College of Medicine Seoul National University Cancer Research Institute, Seoul National University Children's Hospital Seoul Republic of Korea; 13. Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation University of California San Francisco San Francisco California USAShow moreShow less
Source PDF DOI Publisher page
18 days

Is There an Association Between GLP ‐ 1RA Use and Blood Cancer Incidence or Progression?

Authors
Hagop Kantarjian; Ayalew TefferiShow moreShow less
Affiliations
1. Department of Leukemia The University of Texas, MD Anderson Cancer Center Houston Texas USA; 2. Division of Hematology, Department of Medicine Mayo Clinic Rochester Minnesota USAShow moreShow less
Source PDF DOI Publisher page
9 days

Is Bone Marrow Examination Still Required at Diagnosis of Typical Chronic‐Phase Chronic Myeloid Leukemia? Evidence From Paired Peripheral Blood and Bone Marrow Cytogenetics

Authors
Mohammed Al Kurnas; Muluken Megiso; Ayalew Tefferi; Xi Zhang; Kebede H. BegnaShow moreShow less
Affiliations
1. Department of Internal Medicine Mayo Clinic Rochester Minnesota USA; 2. Department of Internal Medicine Jefferson Einstein Philadelphia Hospital Philadelphia Pennsylvania USA; 3. Department of Internal Medicine, Division of Hematology Mayo Clinic Rochester Minnesota USA; 4. Department of Laboratory Medicine and Pathology, Division of Hematopathology Mayo Clinic Rochester Minnesota USAShow moreShow less
Source PDF DOI Publisher page
46 days

Longitudinal Kidney Function Trajectories and Their Association With Hemoglobin and Transfusion Phenotype in Adults With β‐Thalassemia

Authors
Barbara Gianesin; Rodolfo Russo; Giovanni Battista Ferrero; Filomena Longo; Susanna Barella; Raffaella Origa; Roberto Lisi; Roberta Sciortino; Annamaria Pasanisi; Ilaria Foggetti; Eugenia Mariani; Giovan Battista Ruffo; Valeria Maria Pinto; Gian Luca ForniShow moreShow less
Affiliations
1. FORANEMIA ETS Foundation Genoa Italy; 2. Clinica Nefrologica, Dialisi e Trapianto IRCCS Azienda Ospedaliera Metropolitana Policlinico Ospedale San Martino Genoa Italy; 3. SSD Microcitemie e Malattie Rare Ematologiche Ospedale San Luigi Gonzaga, Orbassano Torino Italy; 4. Day Hospital Della Talassemia e Delle Emoglobinopatie Azienda Ospedaliero Universitaria di Ferrara Ferrara Italy; 5. S.C. Centro Delle Microcitemie e Anemie Rare ARNAS G. Brotzu Cagliari Italy; 6. Department of Medical Sciences and Public Health University of Cagliari Cagliari Italy; 7. UOD Talassemia ARNAS Garibaldi Catania Italy; 8. Centro Microcitemia “A. Quarta” Ospedale “A. Perrino” Brindisi Italy; 9. Hematology Unit IRCCS Giannina Gaslini Genoa Italy; 10. UO Ematologia Ospedale Civico Palermo Italy; 11. Hematology and Cellular Therapy Unit IRCCS Azienda Ospedaliera Metropolitana Policlinico Ospedale San Martino Genoa ItalyShow moreShow less
Source PDF DOI Publisher page
83 days

Distinct Consequences of BCOR and BCORL1 Mutations in Myeloid Neoplasms and Bone Marrow Failure

Authors
Atsushi Marumo; Arda Durmaz; Christopher Haddad; Aashray Mandala; Felipe de Almeida Sartori; Akram Abushamma; Serhan Unlu; Xiaorong Gu; Zachary Brady; Matteo D'Addona; Kartik Lakhotiya; Luca Guarnera; Masanori Yoshida; Monika M. Toma; Mark D. Orland; Carlos Bravo‐Perez; Carmelo Gurnari; Koichi Takahashi; Tomasz Skorski; Stephan Hutter; Torsten Haferlach; Marcin Wlodarski; Valeria Visconte; Jaroslaw P. MaciejewskiShow moreShow less
Affiliations
1. Department of Translational Hematology and Oncology Research Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio USA; 2. Department of Hematology Graduate School of Medicine, Nippon Medical School Tokyo Japan; 3. Hematology and Transplant Center, University Hospital “San Giovanni di Dio e Ruggi D'aragona” Salerno Italy; 4. Hematology, Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy; 5. Department of Pediatric Hematology and Oncology Research Research Institute, National Center for Child Health and Development Tokyo Japan; 6. Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine Philadelphia Pennsylvania USA; 7. Department of Hematology and Medical Oncology Hospital Universitario Morales Meseguer, University of Murcia, IMIB‐Pascual Parrilla, CIBERER – Instituto de Salud Carlos III Murcia Spain; 8. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA; 9. Department of Cancer and Cellular Biology Temple University Lewis Katz School of Medicine Philadelphia Pennsylvania USA; 10. Nuclear Dynamics and Cancer Program, Fox Chase Cancer Center Philadelphia Pennsylvania USA; 11. MLL Munich Leukemia Laboratory Munich Germany; 12. St. Jude Children's Research Hospital, Department of Hematology Memphis USAShow moreShow less
Source PDF DOI Publisher page
35 days

New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification

Authors
Naseema Gangat; Paola Guglielmelli; Alessandro M. Vannucchi; Ayalew TefferiShow moreShow less
Affiliations
1. Division of Hematology Mayo Clinic Rochester Minnesota USA; 2. Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms Azienda Ospedaliera Universitaria Careggi, University of Florence Florence ItalyShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does AMERICAN JOURNAL OF HEMATOLOGY take to review a manuscript?

As of 2026-11-17, CrushSCI has 30 complete review records for AMERICAN JOURNAL OF HEMATOLOGY. The fastest paper went from submission to acceptance in 3 days (Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management, received 2026-04-01, accepted 2026-04-04); the slowest took 236 days. The average is 51.4 days and the median is 34 days. The fastest record has an unusually short interval; please check the original source.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.